ClinicalTrials.gov
ClinicalTrials.gov Menu

Expanded Access for CC-4047

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03723096
Expanded Access Status : Available
First Posted : October 29, 2018
Last Update Posted : October 29, 2018
Sponsor:
Information provided by (Responsible Party):
Celgene

Brief Summary:
This is an expanded access program (EAP) for eligible participants designed to provide access to CC-4047.

Condition or disease Intervention/treatment
Multiple Myeloma Drug: CC-4047

Study Type : Expanded Access
Expanded Access Type : Individual Patients
  See clinical trials of the intervention/treatment in this expanded access record.
Official Title: Expanded Access for CC-4047



Intervention Details:
  • Drug: CC-4047
    CC-4047 will be administered orally
    Other Name: Pomalyst, Pomalidomide

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Criteria

Inclusion Criteria:

Exclusion Criteria:


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03723096


Contacts
Contact: Celgene Medical Information 1-888-771-0141 medinfo@celgene.com

Locations
United States, New Jersey
Celgene
Summit, New Jersey, United States, 07901
Sponsors and Collaborators
Celgene

Responsible Party: Celgene
ClinicalTrials.gov Identifier: NCT03723096     History of Changes
Other Study ID Numbers: CC-4047
First Posted: October 29, 2018    Key Record Dates
Last Update Posted: October 29, 2018
Last Verified: October 2018

Keywords provided by Celgene:
Expanded Access
Compassionate Use

Additional relevant MeSH terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Neoplasms
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Pomalidomide
Thalidomide
Immunologic Factors
Physiological Effects of Drugs
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Growth Inhibitors
Antineoplastic Agents
Immunosuppressive Agents
Leprostatic Agents
Anti-Bacterial Agents
Anti-Infective Agents